I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.
The company's management team will deliver a presentation on Tuesday, February 11, 2025, from 4:00 to 4:30 PM ET. The presentation will be accessible via webcast, and the company will also participate in one-on-one meetings during the conference.
I-Mab (NASDAQ: IMAB), un'azienda biotech globale con sede negli Stati Uniti specializzata in agenti di immuno-oncologia di precisione per il trattamento del cancro, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Salute di Oppenheimer. La conferenza virtuale è in programma per l'11-12 febbraio 2025.
Il team di gestione dell'azienda presenterà martedì 11 febbraio 2025, dalle 16:00 alle 16:30 ET. La presentazione sarà accessibile tramite webcast e l'azienda parteciperà anche a incontri individuali durante la conferenza.
I-Mab (NASDAQ: IMAB), una empresa biotecnológica global con sede en EE. UU. que se especializa en agentes de inmuno-oncología de precisión para el tratamiento del cáncer, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La conferencia virtual está programada para el 11 y 12 de febrero de 2025.
El equipo de gestión de la empresa realizará una presentación el martes 11 de febrero de 2025, de 4:00 a 4:30 PM ET. La presentación estará disponible a través de un webcast, y la empresa también participará en reuniones uno a uno durante la conferencia.
I-Mab (NASDAQ: IMAB), 정밀 면역 종양학 약제를 전문으로 하는 미국 기반의 글로벌 생명공학 기업이 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 이 가상 회의는 2025년 2월 11일부터 12일까지 예정되어 있습니다.
회사의 경영진 팀은 2025년 2월 11일 화요일 오후 4시부터 4시 30분(EST)까지 발표를 진행할 예정입니다. 발표는 웹캐스트를 통해 접근 가능하며, 회사는 회의 중에 1대1 미팅에도 참여할 예정입니다.
I-Mab (NASDAQ: IMAB), une entreprise biotechnologique mondiale basée aux États-Unis spécialisée dans les agents d'immuno-oncologie de précision pour le traitement du cancer, a annoncé sa participation à la 35ème Conférence Annuelle sur la Santé de Oppenheimer. La conférence virtuelle est prévue pour les 11 et 12 février 2025.
L'équipe de direction de l'entreprise présentera le mardi 11 février 2025, de 16h00 à 16h30 ET. La présentation sera accessible par webcast et l'entreprise participera également à des réunions en tête-à-tête pendant la conférence.
I-Mab (NASDAQ: IMAB), ein in den USA ansässiges globales Biotech-Unternehmen, das sich auf präzise immunonkologische Medikamente zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an der 35. jährlichen Gesundheits- und Life-Sciences-Konferenz von Oppenheimer angekündigt. Die virtuelle Konferenz ist für den 11. und 12. Februar 2025 geplant.
Das Managementteam des Unternehmens wird am Dienstag, den 11. Februar 2025, von 16:00 bis 16:30 Uhr ET eine Präsentation halten. Die Präsentation wird über einen Webcast zugänglich sein, und das Unternehmen wird auch an Einzelgesprächen während der Konferenz teilnehmen.
- None.
- None.
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.
Details are as follows:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | ||
| Conference Date: | February 11-12, 2025 | |
| Format: | Company Presentation and one-on-one meetings | |
| Presentation Time: | Tuesday, February 11, 2025, 4:00 to 4:30 PM ET | |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/imab/2739496 | |
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com
FAQ
When is I-Mab (IMAB) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch I-Mab's presentation at the Oppenheimer Conference?
What type of meetings will I-Mab participate in at the Oppenheimer Conference 2025?
Is the Oppenheimer Healthcare Conference 2025 virtual or in-person?
What is I-Mab's primary business focus according to the conference announcement?
